OmniSeq News

Schoenborn named CEO at OmniSeq

June 26, 2019 Buffalo News - OmniSeq Inc., a molecular diagnostic laboratory on the Buffalo Niagara Medical Campus, has a new CEO. Margot P. Schoenborn, formerly the company's chief administrative officer, has been promoted to the position.

read more

People in the News

June 26, 2019 GenomeWeb - OmniSeq announced today that it has appointed Margot Schoenborn to succeed Mark Gardner as the firm's CEO.

read more

Margot Schoenborn becomes CEO of fast-growing OmniSeq

Business First - Margot Schoenborn has quite the resume. Now she gets to add yet another interesting professional experience: biotech boss. Schoenborn has been named the CEO of OmniSeq, which develops and sells molecular diagnostic tests that show cancer patients what...

read more
OmniSeq & LabCorp Launch OmniSeq Advance℠ Assay

OmniSeq & LabCorp Launch OmniSeq Advance℠ Assay

New test combines both targeted therapy and immune-oncology biomarkers in a single test with 99% actionability, providing benefits for the treatment of patients and the development of new therapies.ASCO, CHICAGO, ILLINOIS – June 1, 2018 – OmniSeq® , a CAP accredited,...

read more

OmniSeq & LabCorp Launch Tumor-Only MSI NGS Assay

BUFFALO, NEW YORK – April 16, 2018 – OmniSeq®, a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE: LH), a leading global life sciences company, announced today the commercial launch of OmniSeq MSI NGS, a tumor-only,...

read more

Follow Us on Twitter

Congrats to Mary Nesline on her paper newly published in @OncotargetJrnl on Tuesday!

https://t.co/wK2e1xlG9z

OmniSeq is grateful for the continued support and partnership with @LABCORP . Together, we aim to expand patient access to market leading NGS diagnostics throughout the country. #NGS #TargetedTherapy #Immunotherapy #Diagnostics

https://t.co/oxmcNHLWcK

It has been 1 year since the launch of MSI-NGS. OmniSeq allows for MSI testing without the need for matched normal tissue. Let us maximize testing for this important immune oncology biomarker. We identified many MSI-H patients who could not have been tested by PCR! #AACR19

Thank you Wired Magazine and Empire State Development for featuring OmniSeq as a Western New York success story! #ngs #immunotherapy

How One NY Company Is Changing Cancer Treatment

https://t.co/4LFS221n7r

Load More...